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Summary We investigated the effects of our synthetic bombesin gastrin-releasing peptide (GRP) antagonists
and somatostatin analogue RC-160 on the growth of human small-cell lung carcinoma (SCLC) and non-small-
cell lung carcinoma (non-SCLC) lines in nude mice. Athymic nude mice bearing xenografts of the SCLC
NCI-H69 line or non-SCLC NCI-H157 line were treated for 5 and 4 weeks, respectively, with somatostatin
analogue RC-160 or various bombesin/GRP antagonists. RC-160, administered s.c. peritumorally at a dose of
100 ;g per animal per day, inhibited the growth of H69 SCLC xenografts as shown by more than 70%
reduction in tumour volumes and weights, as compared with the control group. Bombesin GRP antagonists.
RC-3440, RC-3095 and RC-3950-II, given s.c. peritumorally at a dose of 20 jig per animal per day, also
inhibited the growth of H69 SCLC tumours. RC-3950-II had the greatest inhibitory effect and decreased
tumour volume and weights by more than 80%. The growth of H-157 non-SCLC xenografts was significantly
reduced by treatment with RC-160, but not with bombesinlGRP antagonist RC-3095. In mice bearing either
tumour model, administration of RC-160 significantly decreased serum growth hormone and gastrin levels.
Specific high-affinity receptors for bombesin and somatostatin were found on membranes of SCLC H69
tumours, but not on non-SCLC H157 tumours. Receptor analyses demonstrated high-affinity binding sites for
epidermal growth factor (EGF) and insulin-like growth factor I (IGF-I) on the membranes of H69 and HI57
tumours. EGF receptors were down-regulated on H69 tumours after treatment with RC-160 and bombesin/
GRP antagonists. The concentration of binding sites for EGF and IGF-I on the H157 tumours was decreased
after treatment with RC-160, but bombesin/GRP antagonist RC-3095 had no effect. These results demonstrate
that bombesin/GRP antagonists inhibit the growth of H-69 SCLC, but not of H-157 non-SCLC xenografts in
nude mice, whereas somatostatin analogue RC-160 is effective in both tumour models. This raises the
possibility that these peptide analogues could be used selectively in the treatment of vanrous subclasses of lung
cancer.
Lung carcinoma is the leading cause of cancer-related deaths
in the western world. It is estimated that in 1992 there were
approximately 168,000 new cases of lung cancer in the US
and that about 146,000 deaths occurred from this disease
(Boring et al., 1992). Treatment of lung cancer is based on
surgery and chemotherapy, but is far from satisfactory, and
new approaches must be explored to improve the therapy.
The growth factors such as bombesin/gastrin-releasing pep-
tide (GRP), epidermal growth factor, (EGF), transforming
growth factor a (TGF-x) and insulin-like growth factor
I(IGF-I) appear to play a role in the proliferation and pro-
gression of lung cancer (Cuttitta et al., 1985; Veale et al.,
1987; Minuto et al., 1988; Siegfried & Owens, 1988; Macaulay
et al., 1990; Tateishi et al., 1991; Damstrup et al., 1992; Sethi
& Rozengurt, 1992; Rabiasz et al., 1992; Moody & Cuttitta,
1993). Bombesin-like peptides have been shown to act as
autocrine growth factors for certain SCLC cell lines (Cuttitta
et al., 1985; Sethi & Rozengurt, 1992; Moody & Cuttitta,
1993). It has also been demonstrated that several human
SCLC and non-SCLC cell lines secrete and respond to IGF-
I, EGF and related polypeptides, including TGF-x (Minuto
et al., 1988; Siegfried & Owens, 1988; Macaulay et al., 1990).
Several groups have reported that the growth of SCLC can
be inhibited in vitro or in vivo by various bombesin/GRP
antagonists (Layton et al., 1988; Mahmoud et al., 1991;
Staley et al., 1991; Langdon et al., 1992; Thomas et al.,
1992), monoclonal antibodies to bombesin (Cuttitta et al.,
1985) and somatostatin analogues (Bogden et al., 1990;
Taylor et al., 1991).
Many potent somatostatin analogues such as o-Phe-Cys-
Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 (RC-160; Octastatin) and
bombesin/GRP antagonists including [D-Tpi6, Leu'3,
*(CH2NH)Leu'4] bombesin (6-14) (RC-3095) were syn-
thesised in our laboratory (Cai et al., 1986, 1992, 1994;
Schally, 1988; Radulovic et al., 1991a) and are being investi-
gated for their ability to inhibit the growth of vanrous
cancers. We have shown that some of these peptide ana-
logues can suppress the growth of prostatic, gastric, pan-
creatic, colorectal, and mammary cancers in vivo (Radulovic
et al., 1991b; Szepeshazi et al., 1991, 1992; Pinski et al.,
1994a, b). The anti-tumour effects of RC-3095 and RC-160
could be linked to a significant decrease in the maximal
binding capacity of EGF receptors in these tumours.
In this study, we have evaluated the effects of somatostatin
analogue RC-160 and three bombesin/GRP antagonists, in-
cluding RC-3095, on the growth of xenografts of the human
SCLC cell line NCI-H69 and the non-SCLC cell line NC1-
H157 in athymic nude mice. In view of the presence of
oestrogen and progesterone receptors in human lung cancer
(Cagle et al., 1990), we also examined whether castration or
administration of the LH-RH antagonist SB-75 (Cetrorelix)
can affect the growth of non-SCLC H157 tumours.
Materials and methods
Peptides
Somatostatin analogue RC-160 (D-Phe-Cys-Tyr-D-Trp-Lys-
Val-Cys-Trp-NH2) originally synthesised by us (Cai et al.,
1986) was made by classical synthesis and supplied by
Debiopharm, Lausanne, Switzerland). Bombesin/GRP an-
tagonists RC-3095 ([D-Tpi6, Leu'3#(CH2NH)Leu'l bombesin
(6-14)), RC-3440 ([Tpi6, Leu'3*(CH2N)Tpi'4 bombesin
(6-16)), RC-3950II ([D-Phe6, Leu'3*(CH,N)Tac'1 bombesin
(6-14)), RC-3005 (His(Bz)2D, D-Trp23, D-Phe2, Leu'-
GRP(14-27)) and RC-3009 (D-Trp23, D-Phe5, Leu27-
GRP(14-27)) were synthesised in our laboratory (Radulovic
et al., 1991a; Cai et al., 1992, 1994). Tpi is 2,3,4,9-tetrahydro-
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lH-pyrido [3,4bjindol-3-carboxylic acid, a conformationally
constrained secondary amine derivate of tryptophan and Tac
is thiazolidine-4-carboxylic acid. The LH-RH antagonist,
[Ac-D-Nal(2)1, D-Phe(4CI)Y, i>Pal(3)3, ID-Cit', D-Alal°lLH-RH
(Cetrorelix, SB-75) was synthesised by solid-phase methods in
our laboratory as well as by Asta Medica (Frankfurt/Main,
Germany) and carefully repurified by high-performance
liquid chromatography (HPLC) (Bajusz et al., 1988). For
subcutaneous administration, RC-160, RC-3095, RC-3440
and RC-3950-II were dissolved in 0.1% dimethylsulphoxide
in saline solution and Cetrorelix in 5% mannitol in
water.
Animals
Male athymic NCr nulmu nude mice, approximately 6 weeks
old on arrival, were obtained from the NCI (Bethesda, MD,
USA) and maintained under pathogen-limited conditions.
Cell lines
The human SCLC cell line NCI-H69, was obtained from the
American Type Cell Culture (ATCC), Rockville, MD, USA
and the non-SCLC cell line NCI-H157, from Dr H. Oie,
NCI-Navy Medical Oncology Branch, Bethesda, MD, USA.
These cell lines were cultured in RPMI-1640 medium supple-
mented with 4 mM L-glutamine, 50 unitsml-I penicilln G
sodium, SOigml-' streptomycin sulphate, 0.125pgml-'
amphotericin B and 10% fetal bovine serum at 3TC in a
humidified 95% air/5% carbon dioxide atmosphere. CeLs
were passaged weekly and routinely monitored for myco-
plasma contamination using a detection kit (Boehringer-
Mannheim, Mannheim, Germany). All culture media com-
ponents were purchased from Gibco (Grand Island, NY,
USA).
Receptor assays
Preparation of membranes for receptor studies was described
previously (Halmos et al., 1993). Iodinated EGF and IGF-I
were purchased from Amersham (Arlington Heights, IL,
USA). Radioiodination of other peptides and receptor bind-
ing of EGF, IGF-I, somatostatin and bombesin/GRP were
performed as previously described (Srkalovic et al., 1989;
Szepeshazi et al., 1992). Complete displacement assays on
tumour membranes were done only once because of the
shortage of tumour material. The LIGAND PC computerised
curve-fitting programme of Munson and Rodbard (1980) was
used to determine the types of receptor binding, dissociation
constant (Kd) values, and the maximal binding capacity (BDj)
of receptors. In order to determine the specificity of the
binding sites for radiolabelled EGF, IGF-I, somatostatin and
bombesin to lung cancer membranes, various structuraly
related and unrelated peptides were tested for their ability to
inhibit the binding of the tracers.
Histologicalprocedure
The histological procedures were the same as described
previously (Szepeshazi et al., 1991, 1992). The number of
mitotic and apoptotic cells per 1,000 cells was determined,
and the percentage area of necrosis in tumour sections was
examined using the point-counting method (Szepeshazi et al.,
1991, 1992), in which the crossing points of an ocular net
that coincide with necrosis in various sections are
counted.
Radiommunoassays
Serum levels of growth hormone were determined by double-
antibody radioimmunoassay (RIA) using materials supplied
by the National Hormone and Pituitary Program of the
National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK). Inter-assay and intra-assay coefficients of
variation were less than 15% and 10% respectively. Serum
gastrin levels were measured by double-antibody RIA with a
kit provided by Becton Dickinson (Orangeburg, NY, USA).
The inter-assay variation was less than 7.0% and the intra-
assay variation about 4.0%.
[3HJThymidine incorporation assay
The ability of peptide analogues to inhibit the incorporation
of [3Hlthymidine into DNA in monolayer cultures of the
human SCLC cell line H69 was assayed as described by
Sondak et al. (1984).
Statistical methods
Statistical analyses of the tumour data were performed using
Duncan's new multiple range test (Steel & Torme, 1976).
Experimentalprotocol
In the first experiment, xenografts were initiated by s.c. injec-
tion of 1 x 10' H69 SCLC cells into the right flanks of five
male mice. Tumours resulting after 7 weeks were aseptically
dissected and mechanically minced; 3 mm3 pieces of tumour
tissue were transplanted s.c. by trocar needle into 60 male
animals under methoxyflurane (Metofane, Pittman-Moore,
Mundelein, IL, USA) anaesthesia. Two weeks after trans-
plantation, when tumours had grown to a volume of ap-
proximately 10mm3, the mice were randomised and divided
into five experimental groups of ten animals each, which
received the following treatment: group 1, saline only; group
2, RC-160 at a dose of 100pgday-' per animal s.c.; group 3,
RC-3095 at a dose of 20pgday-' per animal s.c. group 4,
RC-3440 at a dose of 20jugday-' per animal s.c.; group 5,
RC-3950-II at a dose of 201pgday-'per animal s.c. The
compounds were injected s.c. at about 5 mm distance from
the tumour. The doses ofanalogues were in the oncologically
useful range seleted on the basis of previous extensive
studies in various animal tumour models (Radulovic, 1991b;
Szepeshazi, 1991, 1992; Pinski, 1994a, b).
In the second experiment, xenografts were initiated by s.c.
iniection of 1 x 107 H157 non-SCLC cells into the right
flanks of five male mice. Tumours resulting after 6 weeks
were aseptially diected and mechanically minced; 3mm3
pieces of tumour tissue were transplanted by trocar needle
into 60 male nude mice under methoxyflurane anaesthesia.
One week after transplantation, when tumours had grown to
a volume of approximately 10mm3, the mice were ran-
domised and divided into five experimental groups of ten
animals each, which received the following treatments: group
1, saline only; group 2, castration; group 3, RC-160 at a dose
of 100pgday-' per animal s.c.; group 4, RC-3095 at a dose
of 20pgday-' per animal s.c.; group 5, LH-RH antagonist
SB-75 at a dose of lOOpgday-'per animal s.c. The com-
pounds were injected s.c. at about 5 mm distanc from the
tumour. In both experiments, the tumours were measured
once a week. Tumour volume was calculated as length x wid-
th x height x 0.5236. Tumour volume doubling time was
alculated as previously described (Radulovic et al., 1991b;
Pinski et al., 1994b). At the end of both experiments, mice
were anaesthetised with methoxyflurane, killed by decapita-
tion, trunk blood was collected for analyses, body weights
were recorded and various organs reoved and weighed.
Tumours were cleaned and weighed, and samples were taken
for histology and receptor studies.
Resut
The effects of various treatments on final tumour volume,
body and tumour weights, and tumour doubling time in both
experiments, are shown in Table I. At the end of the
experiments, there were no significant differences in body
weights between the groups.
In experiment I, all three bombesin/GRP antagonists
significantly suppressed growth of SCLC H-69 tumours. RC-888 J. PINSKI et al.
Table I Effect oftreatment with various peptideanalogues on bodyand tumourweight, tumourvolumeand
tumour doubling time in nude mice bearing xenografts of the human SCLC H69 and non-SCLC HI57 cell
lines
Treatment group Tumour volume (mm)r Body weight Tumour weight Tunour doubling
Initial Final (g) (g) time (days)
Evperiment I (SCLC-H69}
Control 10.5 ± 1.6 249.7 ± 182.3 26.3 ± 2.3 0.27 ± 0.19 7.5
RC-3440 10.0 3.3 74.1 84.1* 26.2 +1.3 0.076+ 0.04* 12.1
RC-3095 11.2 1.8 80.2 61.0* 24.0± 2.4 0.081 0.06* 12.2
RC-160 9.8 ± 1.8 66.0 26.5* 24.6 1.2 0.058 0.04* 12.7
RC-3950-I1 11.6±4.1 49.0±47.1* 25.2± 1.7 0.03 0.03* 16.8
Experiment II (non-SCLC H15J7
Control 10.0 2.0 1580.3 ± 455.7 26.5 ± 1.0 1.9 ± 0.3 3.88
Castration 9.6 1.8 1326.7 321.3 25.0 2.2 1.35 ± 0.5 3.95
RC-160 11.1 ±2.6 291.0 207.8* 24.2 ±4.7 0.64 0.3* 6.06
RC-3095 11.2 3.1 913.1 412.3 25.1 4.5 1.1 0.6 4.42
SB-75 9.7 2.0 1301.0 709.8 27.0 2.0 1.4 0.7 4.0
Values are means ± s.d. *P<)0.05 vs control.
3440 and RC-3095 appeared to inhibit tumour growth to a
similar extent. Therapy with bombesin/GRP antagonist RC-
3950-11 was the most effective and resulted in the greatest
inhibition of tumour weight and volume (Figure la, Table I).
Growth of SCLC H69 tumours in animals treated with the
bombesin/GRP antagonists was significantly (P<0.01)
inhibited within 14 days from start of the experiment.
Tumour volume doubling time was prolonged by RC-3950-II
treatment to 16.8 days, as compared with the control group,
which has a doubling time of 7.5 days. Administration of
somatostatin analogue RC-160 also significantly (P<0.01)
inhibited tumour growth from day 14 until the end of the
experiment (Figure la. Table I). The mean tumour weight
was reduced significantly (P<0.01) by RC-160 compared
with the control group (Table I). Tumour volume doubling
time in mice receiving RC-160 was extended to 12.7 days
(Table I).
In expenrment II, only the therapy with somatostatin
analogue RC-160 inhibited growth of non-SCLC H157
tumours (Figure lb, Table I). The final tumour volume and
tumour weight were significantly (P<0.01) reduced in
animals receiving RC-160, compared with those of the con-
trols (Table I). Tumour volume doubling time was prolonged
by RC-160 to 6.06 days, as compared to 3.88 days for the
control group. No significant reduction in final tumour
volume, tumour weight and tumour growth could be found
in the groups treated with bombesin/GRP antagonist RC-
3095 or LH-RH antagonist SB-75. Castration also had no
effect (Figure lb).
Histologically, the SCLC H69 tumours were composed of
uniform undifferentiated cells that were arranged in large
solid nests. The highly cellular tumours contained very little
stoma. The cells were elongated and the oval shaped and
chromatin-rich nuclei were surrounded by narrow dark
cytoplasm. Some of the tumour contained necrotic areas with
inflammatory cell infiltration. The extent of necrosis was
determined with a point counting method using a microscope
ocular net. Mitotic and apoptotic indices were calculated and
the data are shown in Table II. The necrosis was less exten-
sive in the tumours treated with RC-3095 and RC-3950-II;
but these differences from control were not significant statis-
tically. The number of mitotic and apoptotic cells did not
differ significantly from control data. However, the ratio of
apoptotic to mitotic indices was significantly higher in the
group receiving RC-160.
The non-SCLC H157 tumours consisted of large epithelial
cells arranged in solid nests surrounded by very little stroma.
The nuclei of tumour cells were pale, oval, slightly polymor-
phic, containing prominent nucleoli. Necrotic areas and a
granulocytic infiltration could be seen in almost all tumours.
There was no significant difference in the extent of necrosis
among groups. The number of mitoses was not significantly
changed by the treatments, but apoptosis was significantly
enhanced after castration and especially after treatment with
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Fugwe 1 Tumour volumes in nude mice bearing (a) H69 human
SCLC (0, control) during treatment with somatostatin analogue
RC-160 (0), administered s.c. at a dose of 00 Ltgday-' per
animal, and bombesin/GRP antagonists RC-3095 (A), RC-3440
(A) and RC-3950-I1 (0), ainistered s.c. in doses of
20zgday Iper animal, and (b) H157 human non-SCLC (0,
control) during treatment with somatostatin analogue RC-160
(A), injected s.c. at a dose of 100 jlgday' per animal, bombesin/
GRP antagonist RC-3095 (A), administered s.c. at a dose of
20jug day-' per animal, LH-RH antagonist SB-75 (0), given s.c.
at a dose of 100 Lgday-' per animal, and after castration 0).
Vertical bars represent s.e. P<0.05, 'P<0.01 vs control.
SB-75. The ratio of apoptotic to mitotic indices was
significantly higher only in the group treated with SB-75.
The levels of serum growth hormone (GH) and gastrin in
control nude mice and in animals treated with peptide
analogues in both experiments are shown in Table III. In
both experiments, GH and gastrin levels in animals treated
with RC-160 were significantly decreased compared with con-PEPTIDE ANALOGUES IN LIJNG CANCER 8B9
trols. There were no changes in levels of GH and gastrin
after chronic treatment with bombesin/GRP antagonists or
luteinising hormone-releasing hormone (LH-RH) antagonist
SB-75 (Table III).
The characteristics of receptors for bombesin, somato-
statin, EGF and IGF-I in H69 and H157 tumours were
analysed following treatment with peptide analogues in both
experiments, and the results are presented in Table IV. In
experiment I, receptor assays on H69 tumour membranes
showed high-affinity binding sites for bombesin/GRP,
somatostatin, EGF and IGF-I. At the end of the experiment,
Table II Effect of treatment with various peptide analogues and
castration on mitotic and apoptotic indices in SCLC H69 and
non-SCLC HI57 tumours growing in nude mice
Ratio ofapoptotic
Groups Mitotic index Apoptotic index to mitotic indices
Experiment I (SCLC H69)
Control 37.9 ± 2.9 35.4 ± 2.6 0.96 ± 0.1
RC-160 23.0 ± 4.6 42.3 ± 3.2 2.27 + 0.5*
RC-3440 38.5 ± 4.8 32.5 ± 3.4 0.93 ± 0.2
RC-3095 28.8 3.8 36.5 6.8 1.31 0.3
RC-3950-II 49.8 4.8 41.5 1.5 0.85 0.1
Experiment II (non-SCLC H157)
Control 17.3 ± 4.0 2.87 ± 0.5 0.19 ± 0.04
Castration 24.2 ± 6.5 5.00 ± 0.5* 0.29 ± 0.11
RC-160 12.9± 1.2 4.00±0.7 0.35±0.08
RC-3095 19.9 ± 2.4 4.36 ± 0.3 0.25 ± 0.04
SB-75 11.8± 1.5 6.13±0.8* 0.57±0.15*
Values are means ± s.e. *P<0.05 vs control.
Tablem Serum gastrin andgrowthhormone(GH) levelsinnudemice
with xenografts of human SCLC-H69 and non-SCLC HI57 cell lines
after treatment with various peptide analogues
Treatment Gastrin Growth hormone
group (pgml') (ngml-')
Experiment I (SCLC H-69)
Control 130.0 ± 10.8 3.8 ± 0.5
RC-160 68.0 ± 5.5** 2.0 ± 0.5*
RC-3440 92.7 8.2 3.5 ± 0.3
RC-3095 100.7±6.3 4.6 ± 0.5
RC-3950-II 128.2 ± 20.5 5.5 ± 1.2
Experiment II (non-SCLC H-157)
Control 113.7 ± 4.5 6.8 ± 0.8
Castration 98.9 ± 3.4 7.8 ± 2.5
RC-160 57.5 ± 8.7** 3.5 ± 0.3*
RC-3095 136.9± 12.4 8.0± 1.2
SB-75 141.2± 13.8 5.0± 1.3
Valuesaremeans ± s.e. Valuesaremean ± s.e. *P<0.05, **P<0.01
vs control.
concentration of receptors for bombesin/GRP was markedly
dereased by treatment with bombesin/GRP antagonist RC-
3440 and receptors were reduced to non-detectable levels by
antagonists RC-3095 and RC-3950-II (Table MV). The bind-
ing capacity of EGF receptors was decreased after treatment
with somatostatin analogue RC-160 or the bombesin/GRP
antagonists. Therapy with RC-160 increased the binding
capacity of receptors for somatostatin in membranes of H69
tumours (Table LV).
In experiment II, the results of receptor assays on mem-
branes of non-SCLC H157 tumours demonstrated high-
affinity binding sites for EGF and IGF-I, but the receptors
for bombesin/GRP and somatostatin were absent (Table IV).
A marked reduction in EGF binding capacity was observed
after the treatment with RC-160, but not with bombesin/
GRP antagonist RC-3095 or LH-RH antagonist SB-75.
Somatostatin analogue RC-160 also decreased the binding
capacity of IGF-I receptors in membranes of this tumour
(Table IV). No changes in IGF-I binding capacity and
affinity occurred after treatment with RC-3095, SB-75 or
castration (Table IV).
In order to determine the specificity of the binding sites for
EGF, IGF-I, bombesin/GRP and somatostatin on mem-
branes of H-69 SCLC and H-157 non-SCLC, several struc-
turally related and unrelated peptides such as GRP(14-27),
[D-Trp6JLH-RH, somatostatin-14, hEGF and IGF-I were
tested for their ability to inhibit binding of the radioligands.
None of the peptides tested inhibited the binding of radio-
labelled ligands at concentrations as high as 1 gM.
In studies in vitro, somatostatin analogue RC-160 added to
the medium during the 5 days of incubation at concentra-
tions of 0.001 to 10.0 lg ml1 significantly inhibited
['H]thymidine incorporation into DNA of H69 SCLC cells
(Table V). At 0.0 ILg ml-' RC-160, DNA synthesis was sup-
pressed by about 43%. In the presence of bombesin/GRP
antagonists RC-3005 or RC-3009 in the medium at concen-
trations of 5.0 and 25.0 gg ml-' during the 3 days of incuba-
tion, [3H]thymidine incorporation into the DNA of H69 cells
(Table V) was also significantly suppressed.
In the present study, we documented a significant growth-
inhibitory effect of somatostatin analogue RC-160 (Octa-
statin) on the growth of the xenografts of human SCLC H69
cell line in nude mice. This effect was noted after 2 weeks of
administration of RC-160 and persisted for the remaining
treatment penod of 3 weeks. Our results are in agreement
with those previously reported by other groups, demon-
strating inhibitory effects of different somatostatin analogues
on the growth of SCLC cell lines, including H69, in vivo and
in vitro (Bogden et al., 1990; Taylor et al., 1991). In our in
vitro studies, we demonstrated that RC-160 significantly
Table IV Binding characteristics of EGF, IGF-I, bombesin/GRP and somatostatin receptors in membranes ofSCLC H69 and non-SCLC HI57
tumours after in vivo treatment with various peptide analogues
EGF IGF-I Bombesin/GRP Somatostatin
Kd B. Kd B. Kd B. K BK,
Groups (nu' (fmolmg'protein) (nM) (fmolmg' protein) (nM) (fmolmg-'protein) (nM) (fmolmg-'protein)
Experiment I (SCLC-H69)
Control 1.3 278 1.0 294 1.1 420 3.5 450
RC-160 1.6 174 0.9 176 1.3 435 5.5 570
RC-3440 1.0 134 0.7 255 0.9 255 5.0 501
RC-3095 0.7 102 1.7 300 ND ND 4.7 480
RC-3950-II 0.6 93 0.9 226 ND ND 3.6 390
Experiment II (non-SCLC H157)
Control 0.7 249 0.5 257 ND ND ND ND
Castration 0.6 210 0.6 233 ND ND ND ND
RC-3095 0.6 207 0.5 270 ND ND ND ND
RC-160 0.5 100 0.7 129 ND ND ND ND
SB-75 0.7 192 0.6 160 ND ND ND ND
Binding characteristics were obtained from ten-point displacement experiments in triplicate tubes. No s.e. values provided because complete
displacement assays on tumour membranes were done only once because of shortage of tumour material. ND, not detectable.890 J. PINSKI et al.
Table V Inhibitoryeffectofsomatostatin analogue RC-160andbombesin/GRPantagonists
RC-3005 and RC-3009 on incorporation of[3H]thymidine into DNA of SCLC H69 cells
[3H]JThynidine
Dose Treatment incorporation
Peptide analogues ;tgml-daiw' time (davs) (per cent ofcontrol)
I Somatostatin analogue 5
Control 100.0 3.5
RC-160 0.001 81.6 4.6*
0.01 80.0 4.1*
0.1 71.6+3.4**
1.0 73.3 ± 5.0**
10.0 56.6± 12.0**
II Bombesin GRP antagonists 3
Control 100.0± 1.5
RC-3005 1.0 100.0 2.0
5.0 80.1 ± 1.5*
25.0 81.6± 1.3**
RC-3009 1.0 98.4 0.8
5.0 92.7 2.0*
25.0 78.3 ± 2.6**
[3HiThymidine (1-33Ci) was added 24 h before harvesting. Values are mean s.e.
*P<0.05. **P<0.01 vs control.
inhibited tritiated thymidine incorporation into H-69 cells,
indicating some direct effect of this analogue on tumour
growth.
Antineoplastic actions of somatostatin analogues appear to
involve multiple mechanisms. A significant fall in growth
hormone (GH) levels induced by RC-160 could, through
mechanisms involving suppression ofendogenous growth fac-
tors such as IGF-I and IGF-II, be of major importance for
the inhibition of tumour growth (Schally, 1988). Macauley et
al. (1991) previously demonstrated that somatostatin
analogue octreotide reduced IGF-I levels in patients with
SCLC. Membrane receptors for IGF-I were demonstrated in
human SCLC cell lines, and these cells could also be
stimulated by IGF-I (Minuto et al., 1988; Macaulay et al.,
1990). It was reported that immunoreactive IGF-I is detec-
table in primary and metastatic SCLC tumour tissue and in
most SCLC cell lines (Macaulay et al., 1988; Minuto et al.,
1988). In our study, serum GH levels in mice treated with
RC-160 were decreased by about 48% as compared with
control mice. The marked variation of serum GH levels
between H-69 and H-157 control groups could be caused by
different production and/or secretion of growth factors such
as IGF-I by these two lung cancers. High levels of serum
IGF-I might suppress the release of GH through a negative
feedback on the hypothalamus or the anterior pituitary. In
addition, since blood samples from animals bearing H-157
tumours were taken in the morning whereas those from mice
with H-69 tumours were collected in the afternoon, the
difference in GH levels between the two control groups might
also be attributed to diurnal fluctuations of GH levels in
those animals. Sinha et al. (1975) showed previously that
serum levels of GH in two different strains of mice were
usually high during the morning hours.
On the basis of our receptor assay results, which indicate
the presence of high-affinity receptors for somatostatin on
tumour membranes, analogues of somatostatin could also
directly inhibit the growth oflung cancer cells. The inhibitory
effect of somatostatin analogue RC-160 on [3H]thymidine
incorporation was shown on LNCaP prostatic cancer cells in
culture (Gattani et al., 1990). In the MIA PaCa-2 human
pancreatic cancer cell line, somatostatin and its analogue
RC-160 reversed the stimulatory effect of EGF on phos-
phorylation of the tyrosine kinase domain of the EGF recep-
tors and on cell growth (Liebow et al., 1989). These and
other observations (Schally, 1988) suggest that somatostatin
analogues can act as endogenous growth inhibitors in cancer
cells through the activation of tyrosine phosphatase (Liebow
et al., 1989). Furthermore, somatostatin analogues may
inhibit the secretion of bombesin-like peptides and the cAMP
response to vasoactive intestinal peptide (Taylor et al., 1991).
The inhibitory effect of RC-160 on the growth of non-SCLC
H157 tumours observed in our study is probably mainly due
to suppression of GH and IGF-I secretion, since we did not
find somatostatin receptors in membranes of this tumour.
The absence of somatostatin receptors was also observed in
tumour specimens obtained from patients with non-SCLC
(Reubi et al., 1990).
The present study demonstrates a significant inhibitory
effect of bombesin/GRP antagonists RC-3095, RC-3440 and
RC-3950-II on the growth of the SCLC H69 cell line xeno-
grafted into nude mice. In studies in vitro, we found that
structurally related bombesin/GRP antagonists RC-3005 and
RC-3009 significantly inhibited the incorporation of triatiated
thymidine into DNA of H-69 cells, indicating that the
inhibitory effects of this class of bombesin/GRP antagonists
can be attributed at least in part to a direct action. RC-3095
and RC-3950-II also induced a reduction of bombesin/GRP
receptors to non-detectable levels in membranes of this
tumour. Previous studies have shown that bombesin and
GRP are secreted from SCLC cells into tissue culture
medium and that high-affinity receptors for bombesin/GRP
are present in several SCLC cell lines including H69 (Layton
et al., 1988; Mahmoud et al., 1991; Thomas et al., 1992;
Moody & Cuttitta, 1993). Since bombesin stimulates the
clonal growth of SCLC and DNA synthesis in vitro (Carney
et al., 1987) and the growth of SCLC xenografts in nude
mice (Alexander et al., 1988), the inhibition of H69 tumour
growth by bombesin/GRP antagonists appears to be brought
about by blockade of bombesin/GRP receptors on H69
cells.
Previously, we have shown that inhibition of growth of
various cancers, including pancreatic, prostatic, mammary
and colorectal by antagonist RC-3095, was associated with a
major decrease in EGF receptor levels in tumour membranes
(Radulovic et al., 1991b; Szepeshazi et al., 1991,1992; Pinski
et al., 1994a, b). Thus, bombesin/GRP antagonists may act
locally by various mechanisms which result in a reduction in
the available binding sites for EGF. Most non-SCLC and
SCLC cell lines express the EGF receptor (Veale et al., 1987;
Tateishi et al., 1991; Damstrup et al., 1992; Rabiasz et al.,
1992).
The exact molecular mechanism of action of bombesin/
GRP antagonists on EGF receptors is still not well under-
stood. Bombesin initiates a series of intracellular signals,
which cause an increase in inositol 1,4,5-triphosphate, a
mobilisation of Ca2" and diacylglycerol production, lading
to activation of protein kinase C (Zachary et al., 1986;
Langdon et al., 1992; Szepeshazi et al., 1992). Activation of
protein kinase C causes phosphorylation of EGF receptors
on threonine residues. Bombesin and GRP have been shownPEPTIDE ANALOGUES EN LUNG CANCER 891
to enhance the phosphorylation of EGF receptors, and an-
tagonist RC-3095 inhibits these effects in various cancer lines
and cancer specimens (Liebow et al., 1992). These results
suggest that bombesin and GRP may function by up-
regulating EGF receptors and that antagonist RC-3095
prevents this up-regulation (Liebow et al., 1992). Bombesinm
GRP antagonists may also block early cellular events that
precede calcium mobilisation and stimulation of mitogenesis
(Woll & Rozengurt, 1988).
In contrast to its inhibitory effects on SCLC, bombesin/
GRP antagonist RC-3095 did not affect the growth of H157
non-SCLC. Our observations can be explained by the
absence of bombesin/GRP receptors in membranes of this
tumour and are supported by the previously reported finding
that non-SCLC cell lines do not express detectable levels of
bombesin-like peptides (Cuttitta et al., 1985). A study on
various SCLC and non-SCLC cell lines demonstrated that
the GRP gene is expressed in four of six classic SCLC cell
lines, but not in variant SCLC and non-SCLC cell lines
(Cardona et al., 1991).
Since sex hormone receptors have been reported in human
lung tumours (Beattie et al., 1985; Cagle et al., 1990) and the
incidence of pulmonary neoplasms is influenced by sex hor-
mones mi laboratory animals (Noronha & Goodhall et al.,
1983), we felt that it was important to determine whether
castration or administration of LH-RH antagonist SB-75
could inhibit the growth of H157 tumours. However, despite
an increased apoptosis in tumours from castrated or SB-75-
treated animals, no difference in tumour volumes and weights
was found compared with controls. Thus, it appears that
growth factors such as IGF-I play a more important role
than sex hormones in the stimulation of HI57 cells.
In view of the heterogeneity of lung cancers, i.e. non-
SCLC is subclassified into squamous cell carcinoma, adeno-
carcinoma and large cell carcinoma, and SCLC into a classic
and a variant subclass, it is difficult to make general con-
clusions about the utility of our peptide analogues for the
treatment by studying single examples of two subclasses of
lung cancer. Nevertheless, our findings confirm the view,
which is based on a large number of other studies, that
somatostatin analogues such as RC-160 and bombesin/GRP
antagonists such as RC-3095, RC-3440 and RC-3950-II could
be considered as potentially useful agents for treatment of
SCLC. Significant variations in binding sites for these com-
pounds between H-69 SCLC and H-157 non-SCLC xenografts
raise the possibility that such analogues could be used more
selectively in the treatment of various subtypes of lung
cancer. Our work supports the merit of further investigations
based on these and other analogues of somatostatin and
bombesin/GRP antagonists.
Abbmeviatloa LH-RH, luteinising hormone-releasing hormone; GH,
growth hormone; EGF, epidermal growth factor; IGF-I, insulin-like
growth factor I or somatomedin C; TGF-a, transforming growth
factor a; GRP, gastnrn-releasing peptide; SCLC, small-cell lung car-
cinoma; non-SCLC, non-small cell lung carcinoma; Tpi,2,3,4,9-
tetrahydro-lH-pyrido[3,4-b]3-carboxylic acid; HPLC, high-
performance liquid chromatography; cAMP, cyclic adenosine
monophosphate; Tac, thiazolidine-4-carboxylic acid.
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